Phase II study of irinotecan and amrubicin in patients with relapsed non-small cell lung cancer: Okayama Lung Cancer Study Group Trial 0402

References

• Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O’Rourke M, . Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095–103.
   PubMed Web of Science ®Google Scholar
• Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, . Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589–97.
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, . National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123–32.
   PubMed Web of Science ®Google Scholar
• Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, . Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial. Lancet 2008;372:1809–18.
   PubMed Web of Science ®Google Scholar
• Bunn PA. Chemotherapy for advanced non-small-cell lung cancer: Who, what, when, why? J Clin Oncol 2002; 20:23s–33s.
   Google Scholar
• Hsiang YH, Liu LF. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 1988;48:1722–6.
   PubMed Web of Science ®Google Scholar
• Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, . Phase II study of irinotecan, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 1992;10:16–20.
   PubMed Web of Science ®Google Scholar
• Negoro S, Masuda N, Takada Y, Sugiura T, Kudoh S, Katakami N, . Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br J Cancer 2003;88:335–41.
   PubMed Web of Science ®Google Scholar
• Ueoka H, Tanimoto M, Kiura K, Tabata M, Takigawa N, Segawa Y, . Fractionated administration of irinotecan and cisplatin for treatment of non-small-cell lung cancer: A phase II study of Okayama Lung Cancer Study Group. Br J Cancer 2001;85:9–13.
   PubMed Web of Science ®Google Scholar
• Negoro S, Fukuoka M, Nakamura S, Ikegami H, Sugiura T, Ariyoshi Y, . Phase I–II study of amrubicin (SM-5887), a novel 9-amino-anthracycline, by iv administration for 3 consecutive days in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 1995;14:abstr 1105.
   Google Scholar
• Tan KB, Mattern MR, Eng WK, McCabe FL, Johnson RK. Nonproductive rearrangement of DNA topoisomerase I and II genes: Correlation with resistance to topoisomerase inhibitors. J Natl Cancer Inst 1989;81:1732–5.
   PubMed Web of Science ®Google Scholar
• Sugimoto Y, Tsukahara S, Oh-hara T, Liu LF, Tsuruo T. Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Res 1990;50: 7962–5.
   PubMed Web of Science ®Google Scholar
• Kano Y, Suzuki K, Akutsu M, Suda K, Inoue Y, Yoshida M, . Effects of CPT-11 in combination with other anti- cancer agents in culture. Int J Cancer 1992;50:604–10.
   PubMed Web of Science ®Google Scholar
• Hotta K, Takigawa N, Kiura K, Tabata M, Umemura S, Ogino A, . Phase I study of irinotecan and amrubicin in patients with advanced non-small-cell lung cancer. Anticancer Res 2005;25:2429–34.
   PubMed Web of Science ®Google Scholar
• Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest 1997;111:1718–23.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–81.
   Web of Science ®Google Scholar
• Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non- small-cell lung cancer. J Clin Oncol 2004;22:3852–9.
   PubMed Web of Science ®Google Scholar
• Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: A literature based meta-analysis of randomised trials. Ann Oncol 2004;15:1782–9.
   PubMed Web of Science ®Google Scholar
• Hotta K, Matsuo K. Long-standing debate on cisplatin-versus carboplatin-based chemotherapy in the treatment of advanced non-small-cell lung cancer. J Thorac Oncol 2007;2:96.
   PubMed Web of Science ®Google Scholar
• Fukuda M, Ohe Y, Kanzawa F, Oka M, Hara K, Saijo N. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin. Anticancer Res 1995;15:393–8.
   PubMed Web of Science ®Google Scholar
• Ohe Y, Nakagawa K, Fujiwara Y, Sasaki Y, Minato K, Bungo M, . In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines. Cancer Res 1989;49:4098–102.
   PubMed Web of Science ®Google Scholar
• Shibayama T, Hotta K, Takigawa N, Tada A, Ueoka H, Harita S, . A phase I and pharmacological study of amrubicin and topotecan in patients of small cell lung cancer with relapsed or extensive-disease small cell lung cancer. Lung Cancer 2006;53:189–95.
   PubMed Web of Science ®Google Scholar
• Inoue A, Sugawara S, Yamazaki K, Maemondo M, Suzuki T, Gomi K, . Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol 2008;26:5401–6.
   PubMed Web of Science ®Google Scholar
• Kato T, Nokihara H, Ohe Y, Yamamoto N, Sekine I, Kunitoh H, . Phase II trial of amrubicin in patients with previously treated small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 2006;24:abstr 7061.
   Google Scholar
• Kaneda H, Kurata T, Tamura K, Uejima H, Nakagawa K, Fukuoka M. A phase I study of irinotecan in combination with amrubicin for advanced lung cancer patients. Anticancer Res 2006;26:2479–85.
   PubMed Web of Science ®Google Scholar
• Innocenti F, Kroetz DL, Schuetz E, Dolan ME, Ramírez J, Relling M, . Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol 2009;27:2604–14.
   PubMed Web of Science ®Google Scholar
• Saito Y, Maekawa K, Ozawa S, Sawada J. Genetic polymorphisms and haplotypes of major drug metabolizing enzymes in East Asians and their comparison with other ethnic populations. Curr Pharmacogenomics 2007;5:49–78.
   Google Scholar
• Theodoulou M, Hudis C. Cardiac profiles of liposomal anthracyclines: Greater cardiac safety versus conventional doxorubicin? Cancer 2004;100:2052–63.
   PubMed Web of Science ®Google Scholar
• Noda T, Watanabe T, Kohda A, Hosokawa S, Suzuki T. Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs. Invest New Drugs 1998; 16:121–8.
   PubMed Web of Science ®Google Scholar
• Yana T, Negoro S, Takada Y, Yokota S, Fukuoka M. Phase II study of amrubicin (SM-5887), a 9-amino- anthracycline, in previously untreated patients with extensive stage small-cell lung cancer (ES-SCLC): A West Japan Lung Cancer Group Trial. Proc Am Soc Clin Oncol 1998;17:450a(abstr 1734).
   Google Scholar
• Ohe Y, Negoro S, Matsui K, Nakagawa K, Sugiura T, Takada Y, . Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive stage small cell lung cancer (ED-SCLC). Proc Am Soc Clin Oncol 2004;23: 664(abstr 7206).
   Google Scholar